STUDY DESIGN AND METHODS:
Children with sickle cell anemia on chronic transfusion therapy were followed prospectively for 12 months. All patients received units serologically matched for C/c, E/e, and K; patients with prior red blood cell (RBC) antibodies had additional matching for Fy a , Jk b , and any previous alloantibodies. Patients' RBC antigen genotypes, determined by multiplexed molecular assays (PreciseType Human Erythrocyte Antigen, and RHCE and RHD BeadChip, Immucor) were compared to genotypes of transfused RBC units to assess for antigen mismatches. Decline in hbA (DHbA) from posttransfusion to the next transfusion was calculated for each transfusion episode.
RESULTS: Sixty patients received 789 transfusions, 740
with DHbA estimations, and 630 with donor Human Erythrocyte Antigen genotyping. In univariate mixedmodel analysis, DHbA was higher in patients with past RBC antibodies or splenomegaly and lower in patients with splenectomy. RBC antigen mismatches were not associated with DHbA. In multivariate linear mixedeffects modeling, DHbA was associated with RBC antibodies (2.70 CONCLUSIONS: HbA decline was increased among patients with sickle cell anemia with prior immunologic response to RBC antigens and decreased among those with prior splenectomy, demonstrating that recipient immunologic characteristics influenced the clearance of transfused RBCs. C hronic transfusion therapy (CTT) for sickle cell anemia (SCA) is an essential treatment for the prevention of severe sickle complications such as stroke. [1] [2] [3] CTT is effective at preventing red blood cell (RBC) sickling by two mechanisms: (1) with frequent transfusions, nonsickle hemoglobin A (HbA)-containing erythrocytes predominate in the circulation compared to endogenous RBCs, and (2) by maintaining higher hemoglobin (Hb) levels, endogenous erythropoiesis of sickle erythrocytes is suppressed. The effectiveness of CTT is monitored by measuring the percentage of sickle Hb (HbS), total Hb, and reticulocytes prior to each transfusion. 4 HbS level is influenced by several factors, including erythopoietic drive, hemolysis of endogenous sickle erythrocytes, and the clearance of transfused RBCs. Individual variation in HbS suppression exists. Some patients achieve desired Hb and HbS goals with simple transfusions monthly, while others have poor suppression of HbS, necessitating either an increase in transfusion volume or frequency or implementation of exchange transfusion therapy. 5, 6 Better understanding of factors that influence the kinetics of transfused RBC clearance in CTT patients could facilitate development of transfusion practices that more effectively suppress HbS.
Patients with SCA have a high prevalence of RBC alloimmunization, ranging from 18% to over 45%. [7] [8] [9] [10] Alloimmunization can result in hemolytic transfusion reactions (HTRs) and limits the supply of compatible RBC units for future transfusions. [10] [11] [12] Although antigen matching for C/c, E/e, K, and potentially other antigens has been shown to reduce the rate of alloimmunization in SCA, 13 , V, VS), and the ability to obtain accurate antigen typing in patients with recent RBC transfusion or with RBC alloantibodies or autoantibodies. 15 HTRs are an extreme example of rapid clearance of transfused RBCs, mediated by antibody production and complement activation. Although HTRs and alloimmunization events result in increased HbA clearance, it is not known if RBC antigen mismatches independently influence HbA clearance in the absence of serologically detected RBC antibodies. Retrospective analysis of transfusion requirements during myeloablative bone marrow transplantation in sickle cell disease have suggested that increased antigen matching was associated with decreased transfusion volumes, suggesting improved RBC survival with antigen matching. 16 The aims of this study were to (1) determine the rate of clearance of donor HbA-containing erythrocytes following transfusions in children with SCA on CTT and (2) determine the associations of HbA clearance with RBC minor antigen mismatches (determined by patient and donor RBC genotyping), recipient immunologic characteristics, and donor unit characteristics.
MATERIALS AND METHODS
A prospective observational study of children and adolescents aged 3 to 20 years with SCA (HbSS) on CTT for at Electronic medical records and the blood bank Laboratory Information Systems of CHOA and CNMC were reviewed to identify subjects' CTT start date, history of splenectomy, splenomegaly present on physical examination at the time of transfusion, and RBC antibody histories, including antibodies detected at either the current or previous institutions. At CHOA and CNMC, all RBC units for patients with sickle cell disease were HbS negative, prestorage leukoreduced, and serologically matched for C/c, E/e, and K antigens (Category 1 matching). For patients with one or more clinically significant alloantibodies or some cases of warm autoantibodies, RBC units were selected by extended serologic matching for Fy a and Post HbA g=dL
HbA decline (DHbA, g/dL/28 d) was calculated as the difference between the estimated posttransfusion HbA and the pretransfusion HbA of the subsequent transfusion episode, divided by the transfusion interval (number of days between HbA measurements), then multiplied by 28 to normalize all values to the change in HbA per 4 weeks. The unit Hct was estimated based on quality analysis data from each blood supplier for the unit's preservative solution (citrate-phosphate-dextrose-adenine, additive solution, or frozen/deglycerized). If the blood supplier range of estimated unit Hct had a range of greater than 10%, the posttransfusion HbA and thus DHbA were not estimated, and those units were excluded from analysis due to potentially high inaccuracy of the DHbA estimation. For each transfusion episode, an antigen mismatch was defined as the number of units mismatched divided by the total number of units transfused (e.g., in a transfusion episode of three units, if an antigen was mismatched in one unit, the mismatch for that transfusion episode was 0.33 or 33% of the transfused RBCs were mismatched for that antigen). In addition to individual antigens, mismatches were examined per blood group, in which the mismatch per group was the sum of the individual antigen mismatches (e.g., Rh mismatches were the sum of V, VS, D, C/c, and E/e mismatches per transfusion). Antigen groups were excluded from analysis if the frequency of mismatch for all antigens in that group was less than 2% (e.g., Diego, Landsteiner-Weiner, Sciana).
Statistical analysis
For transfusions in which posttransfusion laboratory measurements were done, measured post-HbA was compared to estimated post-HbA by Bland-Altman limits of agreement and intraclass correlation coefficient. Bias was assessed as the median difference between measured and estimated HbA, and precision was assessed as the interquartile range (IQR) of the bias. Accuracy was assessed as the percentage of HbA estimates that were within 10% (P 10 ) and 15% (P 15 ) of the measured HbA. Intrapatient variance in DHbA was assessed as the IQR of DHbA per patient; due to nonnormality of the data, the IQR of DHbA was compared to RBC antibody status by Wilcoxon rank sum test.
At the patient level, univariate comparisons of RBC antibody status were made by t test for continuous variables or by chi-squared test for categorical variables. At the transfusion episode level, univariate comparisons of RBC antibody status with transfusion characteristics and pretransfusion laboratory values were done by linear mixed modeling to account for repeated measures on identical patients. Mixed-effects modeling was used in all analyses of transfusion episodes to account for both random effects (individual patients and transfusion episodes) and the fixed effects of interest (patient and transfusion characteristics). Thus, mixed-effects modeling can account for repeated measures (i.e., multiple transfusions) per patient, allowing for generalizability of the analysis. Least-squares means were used to compare continuous variables with repeated measures.
Univariate associations of DHbA with categorical variables (splenectomy, splenomegaly, and prior RBC antibodies) and with continuous variables (age, unit age, transfusion volume, total antigen mismatches, and the Hb, HbS, and reticulocyte values prior to the next transfusion) were determined by linear mixed modeling. The effects of individual blood group mismatches on DHbA also were assessed by linear mixed modeling, stratifying by Category 1 versus Category 2 to account for the inherent differences in antigen matching between these two groups of transfusion populations. Variables with a p value of 0.20 or less in univariate analysis were introducted into multivariable linear mixed modeling to examine the effect of patient and transfusion characteristics on DHbA; additionally, variables with potential interaction were introduced into the model.
RESULTS
There were 60 SCA patients (24 with past RBC alloimmunization or RBC autoantibodies) who received 789 transfusions during the study. Of these, 49 transfusions were excluded for the inability to estimate DHbA (due to either lack of pretransfusion HbA measurement or estimated unit Hct), and 110 transfusions in which more than one unit was missing RBC genotyping. Thus, 630 transfusions (395 Category 1 antigen matching, 235 Category 2) were available to assess the relationships between DHbA and antigen mismatches (Fig. 1) .
Characteristics of the 60 patients and 789 transfusion episodes are shown in Table 1 .
Posttransfusion HbA estimation
There were 217 (27.5%) transfusions (183 simple, 34 partial manual exchange) in which posttransfusion HbA was both measured and estimated. The mean posttransfusion HbA was 9.64 g/dL (range, 6.28-13.1 g/dL) by direct measurements vs. 9.32 g/dL (range, 5.65-12.8 g/dL) by estimation. Estimated HbA had a negative bias of 0.32 g/ dL (95% confidence interval [CI], 0.23-0.41), with a precision of 0.81 g/dL (95% CI, 0.61-1.09). The intraclass correlation coefficient between estimated and measured HbA was 0.75, indicating that the proportion of betweencluster (i.e., patient) variance to the total variance was high. Accuracy of the estimated HbA within 10% of measured HbA was 82.5% (P 10 ) and within 15% of measured HbA was 93.6% (P 15 ). Bland-Altman limit of agreement plot for measured versus estimated posttransfusion HbA is shown in Fig. 2 .
HbA decline (DHbA)
There were 740 transfusion episodes with DHbA estimations. Intrapatient variability in DHbA, demonstrated by the IQR of DHbA, is shown in Fig. 3 In univariate mixed-effects analyses, DHbA was significantly lower in patients with splenectomy than those without splenectomy (least-squares means, 2.14 vs. Increased DHbA was associated with lower total Hb (p < 0.0001), higher HbS percentage (p < 0.0001), and higher reticulocyte count (p < 0.0001) prior to the next transfusion episode, demonstrating the association of DHbA with suppression of erythropoiesis.
Antigen mismatches
For the 630 transfusions with donor antigen genotyping, the mean number of antigen mismatches was 3.3 (range, 0-9 mismatches), with a mean of 3.7 mismatches for Category 1 and 2.6 mismatches for Category 2 transfusions (p < 0.0001). The frequency of individual antigen mismatches per transfusion episode has been previously described. 18 In univariate mixed-effects analyses, stratified by antigen-matching category, the total number of antigen mismatches was not associated with DHbA for Category 1 transfusions (p 5 0.097) or Category 2 transfusions (p 5 0.39). There were no significant associations between specific antigen mismatches or blood group mismatches (Rh, Kell, Duffy, Kidd, M/N and S/s/U, Lutheran, Colton, and Dombrock groups) and DHbA while clustering on each patient, as assessed by linear mixed models and also accounting for patients' RBC antibody status (Table 2) .
New alloimmunization events
There were five new alloantibodies detected after four transfusion episodes during the study period: one with anti-Js a and anti-Wr a detected after the same transfusion, one with anti-Js a , one with anti-Go a , and one with antibody of undetermined specificity (Table 3) . There was no difference in 
Multivariate mixed-effects modeling
Because the age of blood was significantly lower in patients with past RBC antibodies, both RBC antibodies and age of blood were jointly assessed in a multivariable linear mixed model. There was a significant effect of RBC antibodies on DHbA (p 5 0.021) but no significant effects observed among either the mean unit age per transfusion (p 5 0.10) or the maximum age of any unit per transfusion (p 5 0.20). Thus, when controlling for age of the units, patients with past RBC antibody response had significantly higher DHbA. In multivariate linear mixed modeling (Table 4) , past RBC antibody response (p 5 0.0028) and splenomegaly (p 5 0.019) were positively associated with DHbA, while splenectomy (p 5 0.011) was negatively associated with DHbA. 
DISCUSSION
The ability of CTT to prevent complications of SCA is dependent upon maintaining a low percentage of circulating HbScontaining erythrocytes, which in turn is dependent on the rates of clearance of both endogenous and transfused RBCs from circulation. As demonstrated within this study, the clearance of transfused RBCs (reflected by DHbA) is highly variable, both among different patients and among sequential transfusions within the same patient. Elucidating the factors that influence clearance of transfused RBCs is important to ultimately determine if certain characteristics of RBC units can be selected to minimize HbA decline and therefore optimize transfusion therapy to SCA patients. In this study, we showed significantly greater decline in HbA in patients with prior antibody response to RBC antigens, while controlling for the age of the transfused units. Although patients with past RBC antibodies received transfusions that were matched for both the existing antibodies and for a greater number of RBC antigens (to prevent induction of more RBC alloantibodies), neither the total number of antigen mismatches nor specific groups of antigen mismatches showed significant association with DHbA. Thus, the increased DHbA in patients with prior RBC antibodies does not appear to be related to the specific antigen matches, but rather to the existence of a prior immune response to transfused erythrocytes. Patients with SCA with alloimmunization are known to have an increased risk for future alloimmunization, 21 even with more stringent antigen matching. 18 These findings strongly suggest that these 40 Conversely, in a murine model of alloimmunization, donor RBCs that were subjected to pretransfusion oxidant stress to cause rapid posttransfusion clearance by the reticuloendothelial system were significantly more immunogenic than donor RBCs with longer posttransfusion survival, suggesting that clearance rate by the reticuloendothelial system influences alloimmunization respones. 41 Additional studies are certainly needed to determine if accelerated RBC removal predicts RBC alloimmunization, if it is a consequence of RBC alloimmunization, or if it is only correlative and not directly related to RBC alloimmunization. A striking finding of the study was the intrapatient variability in DHbA, which suggests that characteristics of the donor and/or stored RBC unit may have a significant influence on the clearance of transfused RBCs apart from recipient immunologic characteristics. Antigen mismatches between donor and recipient (whether analyzed as individual antigens or aggregated blood group mismatches) showed no association with DHbA. The storage age of the transfused units was not associated with HbA decline following transfusion, suggesting that in vivo survival of RBCs was not influenced by storage for the range of unit ages in this study. This analysis was not designed to assess the effect of the oldest units on HbA decline and included a full spectrum of ages from 3 to 42 days (median 18 days), with few units reaching the maximum allowable storage time of 42 days. Category 2 matched units were significantly younger than Category 1 units in this study. This may be related to the need to identify repeat donors who meet the specific antigen-matching requirements of the Category 2 patients. As antigen mismatches and unit age were not significant predictors of DHbA, further donor characteristics should be investigated to determine the impact of in vivo survival of transfused RBCs, including metabolomics profiles of donor RBCs that may be associated with RBC survival and response to oxidative stress. A limitation of this study was the lack of direct measurement of posttransfusion HbA for the majority of transfusions and the lack of direct measurement of transfused RBC survival by labeling techniques such as biotin or chromium-51 labeling of transfused RBCs. While the posttransfusion HbA estimates showed high accuracy and low bias, the use of estimated (rather than directly measured) unit Hct to estimate posttransfusion HbA did introduce error, with some post-HbA estimates demonstrating low precision. The need to estimate posttransfusion HbA thus does introduce some error and bias into DHbA, the primary outcome of interest. To account for this bias, estimated post-HbA (not measured post-HbA) was used to calculate DHbA in all transfusion episodes, in order to provide a uniform approach. While DHbA correlates appropriately with subsequent Hb and reticulocyte counts, it is a surrogate for the true outcome of interest, which is the clearance of transfused RBCs. Transfused RBCs remain detectable in vivo for up to 4 months post-transfusion; thus, the decline in HbA in a given time interval reflects the clearance of RBCs from multiple recent transfusions, not solely the most recent one. Direct measurement of RBC survival, with labeling of RBC units prior to transfusion, would provide a more accurate reflection of transfusion clearance. Another limitation is the lack of exact spleen measurements by radiologic imaging, which would provide a more sensitive measure of spleen presence and enlargement than would physical examination. Finally, this study focuses on children and adolescents with SCA, who potentially could have different kinetics of RBC clearance than adults, given possible differences in splenic function and erythropoietic drive in children as compared to adults; therefore, the aims of this study bear replication in adult SCA populations.
In summary, HbA decline following chronic transfusion episodes in children with SCA had interpatient and intrapatient variability over 12 months of transfusion episodes. This variability suggests that HbA decline is influenced by multiple donor and recipient characteristics. Whereas the overall number of RBC antigen mismatches did not have a significant effect on HbA decline, patients who had previously developed RBC antibodies and received transfusions with extended antigen matching had higher HbA decline than patients without past RBC antibodies. Decline in HbA was lower in patients with splenectomy, while two patients with splenomegaly demonstrated higher HbA decline. Immunologic and reticuloendothelial system characteristics of SCA patients thus appear to influence the clearance of transfused RBCs, even in the absence of detectable RBC antibody.
